| Medical and Health Sciences | 2021-2025 | 453 | CA 14 | 99.90 |
| Biological Sciences | 2021-2025 | 311 | CA 9 | 99.69 |
| Economics and Finance | 2021-2025 | 171 | CA 4 | 99.49 |
| Chemistry | 2021-2025 | 500 | CA 6 | 97.05 |
| Econometrics and Quantitative Economics | Lifetime | 812 | CA 23 | 99.25 |
| Reproductive Medicine | Lifetime | 284 | CA 10 | 98.37 |
| Computational Theory and Mathematics | Lifetime | 562 | CA 15 | 97.50 |
| Medicinal and Pharmaceutical Chemistry | Lifetime | 96 | CA 3 | 94.92 |
| Pharmacology | Lifetime | 667 | CA 20 | 90.87 |
| Emergency Medical Services | Lifetime | 938 | CA 47 | 84.47 |
| Pharmaceutical Science | Lifetime | 725 | CA 13 | 82.65 |
| Chemical Biology and Bioorganic Chemistry | Lifetime | 187 | CA 3 | 78.03 |
| Applied Microbiology and Biotechnology | Lifetime | 234 | CA 14 | 79.58 |
| Health, Labor and Public Economics | Lifetime | 121 | CA 4 | 74.19 |
| Immunology and Allergy | Lifetime | 945 | CA 42 | 69.02 |
| Endocrinology | Lifetime | 689 | CA 33 | 65.24 |
| Microbiology | Lifetime | 766 | CA 42 | 59.05 |
| Biotechnology | Lifetime | 987 | CA 25 | 49.28 |
| Virology | Lifetime | 705 | CA 17 | 39.80 |
| Econometrics and Quantitative Economics | 2021-2025 | 163 | CA 4 | 99.39 |
| Medical Physiology | 2021-2025 | 87 | CA 4 | 98.92 |
| Molecular Biology | 2021-2025 | 222 | CA 5 | 99.04 |
| Reproductive Medicine | 2021-2025 | 58 | CA 2 | 98.29 |
| Oncology | 2021-2025 | 181 | CA 2 | 98.62 |
| Public, Environmental and Occupational Health | 2021-2025 | 257 | CA 19 | 97.77 |
| Immunology | 2021-2025 | 176 | CA 5 | 96.27 |
| Computational Theory and Mathematics | 2021-2025 | 146 | CA 3 | 96.66 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 366 | CA 7 | 92.71 |
| Genetics | 2021-2025 | 365 | CA 17 | 90.14 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 677 | CA 29 | 91.68 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 416 | CA 37 | 90.19 |
| Medical Genetics | 2021-2025 | 204 | CA 6 | 90.76 |
| Cancer Research | 2021-2025 | 227 | CA 6 | 87.57 |
| Chemical Biology and Bioorganic Chemistry | 2021-2025 | 27 | CA 1 | 86.36 |
| Infectious Diseases | 2021-2025 | 619 | CA 17 | 85.96 |
| Medicinal and Pharmaceutical Chemistry | 2021-2025 | 36 | CA 1 | 84.28 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 747 | CA 46 | 86.03 |
| Clinical Neurology | 2021-2025 | 480 | CA 22 | 82.05 |
| Hematology | 2021-2025 | 343 | CA 17 | 82.35 |
| Clinical Pharmacology | 2021-2025 | 410 | CA 31 | 81.01 |
| Immunology and Allergy | 2021-2025 | 168 | CA 6 | 81.40 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 537 | CA 23 | 81.16 |
| Biochemistry | 2021-2025 | 96 | CA 3 | 80.74 |
| Organizational Behavior and Human Resource Management | 2021-2025 | 503 | CA 32 | 79.38 |
| Pharmaceutical Science | 2021-2025 | 180 | CA 3 | 78.73 |
| Neuroscience of Neurology | 2021-2025 | 342 | CA 21 | 71.79 |
| Cellular and Molecular Neuroscience | 2021-2025 | 312 | CA 20 | 69.56 |
| Emergency Medical Services | 2021-2025 | 171 | CA 5 | 70.82 |
| Pathology and Forensic Medicine | 2021-2025 | 536 | CA 25 | 71.11 |
| Veterinary Science and Animal Health | 2021-2025 | 205 | CA 18 | 69.20 |
| Applied Microbiology and Biotechnology | 2021-2025 | 113 | CA 6 | 69.03 |
| Rheumatology | 2021-2025 | 523 | CA 30 | 65.80 |
| Biotechnology | 2021-2025 | 156 | CA 4 | 64.06 |
| Clinical Biochemistry | 2021-2025 | 76 | CA 2 | 62.97 |
| Cell Biology | 2021-2025 | 295 | CA 10 | 57.41 |
| Biotechnology and Related Fields | Lifetime | 1 | CA 1 | 99.31 |
| Science, Research, and Medicine | Lifetime | 1 | CA 1 | 98.97 |
| Biomedical Ethics and Regulation | Lifetime | 18 | CA 3 | 98.47 |
| Pharmaceutical Economics and Policy | Lifetime | 65 | CA 3 | 98.64 |
| Computational Drug Discovery Methods | Lifetime | 240 | CA 7 | 98.64 |
| Biosimilars and Bioanalytical Methods | Lifetime | 55 | CA 6 | 98.51 |
| Biological Research and Disease Studies | Lifetime | 2 | CA 1 | 96.27 |
| Chemical Reactions and Isotopes | Lifetime | 110 | CA 4 | 98.27 |
| Health and Medical Research Impacts | Lifetime | 73 | CA 10 | 97.49 |
| Pharmaceutical studies and practices | Lifetime | 312 | CA 20 | 97.49 |
| CAR-T cell therapy research | Lifetime | 742 | CA 20 | 98.04 |
| Genetics, Bioinformatics, and Biomedical Research | Lifetime | 123 | CA 6 | 95.70 |
| Protein Degradation and Inhibitors | Lifetime | 480 | CA 17 | 96.52 |
| Click Chemistry and Applications | Lifetime | 909 | CA 21 | 95.01 |
| Biomedical and Engineering Education | Lifetime | 345 | CA 11 | 91.49 |
| Advanced Breast Cancer Therapies | Lifetime | 868 | CA 21 | 93.36 |
| Pharmaceutical industry and healthcare | Lifetime | 263 | CA 24 | 92.07 |
| Nutrition, Genetics, and Disease | Lifetime | 937 | CA 38 | 91.51 |
| PARP inhibition in cancer therapy | Lifetime | 856 | CA 35 | 91.72 |
| 14-3-3 protein interactions | Lifetime | 684 | CA 28 | 80.92 |
| Academic Publishing and Open Access | Lifetime | 540 | CA 34 | 61.14 |
| Biomedical Ethics and Regulation | 2021-2025 | 2 | CA 1 | 99.48 |
| Biotechnology and Related Fields | 2021-2025 | 1 | CA 1 | 99.47 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 15 | CA 1 | 98.78 |
| Science, Research, and Medicine | 2021-2025 | 1 | CA 1 | 99.47 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 120 | CA 16 | 98.36 |
| CAR-T cell therapy research | 2021-2025 | 150 | CA 4 | 98.89 |
| Health and Medical Research Impacts | 2021-2025 | 16 | CA 3 | 95.54 |
| Pharmaceutical Economics and Policy | 2021-2025 | 33 | CA 3 | 96.75 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 170 | CA 4 | 96.63 |
| Computational Drug Discovery Methods | 2021-2025 | 255 | CA 6 | 96.36 |
| CRISPR and Genetic Engineering | 2021-2025 | 253 | CA 4 | 95.13 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 366 | CA 9 | 96.18 |
| Chemical Reactions and Isotopes | 2021-2025 | 24 | CA 1 | 91.23 |
| Peptidase Inhibition and Analysis | 2021-2025 | 359 | CA 5 | 93.10 |
| Click Chemistry and Applications | 2021-2025 | 211 | CA 2 | 92.54 |
| Pharmaceutical studies and practices | 2021-2025 | 174 | CA 11 | 90.03 |
| Protein Degradation and Inhibitors | 2021-2025 | 405 | CA 13 | 92.05 |
| Cell Adhesion Molecules Research | 2021-2025 | 231 | CA 3 | 85.51 |
| Advanced Breast Cancer Therapies | 2021-2025 | 643 | CA 12 | 88.22 |
| Viral Infections and Immunology Research | 2021-2025 | 750 | CA 20 | 84.40 |
| HER2/EGFR in Cancer Research | 2021-2025 | 841 | CA 10 | 86.73 |
| Cancer Research and Treatments | 2021-2025 | 665 | CA 3 | 81.87 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 998 | CA 44 | 84.81 |
| Nutrition, Genetics, and Disease | 2021-2025 | 395 | CA 21 | 79.66 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 367 | CA 11 | 75.09 |
| Cancer therapeutics and mechanisms | 2021-2025 | 926 | CA 5 | 72.53 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 884 | CA 28 | 71.97 |
| Innovation Policy and R&D | 2021-2025 | 424 | CA 4 | 59.65 |